INFINITY PHARMACEUTICALS INC (INFI) Fundamental Analysis & Valuation

NASDAQ:INFI • US45665G3039

Current stock price

0.0447 USD
-0.04 (-46.98%)
At close:
0.04 USD
0 (-10.51%)
After Hours:

This INFI fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. INFI Profitability Analysis

1.1 Basic Checks

  • INFI had negative earnings in the past year.
  • INFI had a negative operating cash flow in the past year.
INFI Yearly Net Income VS EBIT VS OCF VS FCFINFI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 -50M -100M -150M

1.2 Ratios

  • The profitability ratios for INFI are negative, so there is not much use analyzing them.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
INFI Yearly ROA, ROE, ROICINFI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 0 200 -200 -400 -600

1.3 Margins

  • INFI's Gross Margin of 39.70% is fine compared to the rest of the industry. INFI outperforms 76.94% of its industry peers.
  • INFI does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 39.7%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
INFI Yearly Profit, Operating, Gross MarginsINFI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 0 -500 -1K -1.5K -2K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

1

2. INFI Health Analysis

2.1 Basic Checks

  • INFI does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • INFI has more shares outstanding than it did 1 year ago.
  • INFI has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
INFI Yearly Shares OutstandingINFI Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M 80M
INFI Yearly Total Debt VS Total AssetsINFI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M 80M 100M

2.2 Solvency

  • Based on the Altman-Z score of -63.75, we must say that INFI is in the distress zone and has some risk of bankruptcy.
  • INFI has a Altman-Z score of -63.75. This is amonst the worse of the industry: INFI underperforms 98.02% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -63.75
ROIC/WACCN/A
WACC9.35%
INFI Yearly LT Debt VS Equity VS FCFINFI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 0 50M -50M -100M -150M

2.3 Liquidity

  • INFI has a Current Ratio of 1.65. This is a normal value and indicates that INFI is financially healthy and should not expect problems in meeting its short term obligations.
  • With a Current ratio value of 1.65, INFI is not doing good in the industry: 83.86% of the companies in the same industry are doing better.
  • A Quick Ratio of 1.65 indicates that INFI should not have too much problems paying its short term obligations.
  • With a Quick ratio value of 1.65, INFI is not doing good in the industry: 82.70% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 1.65
Quick Ratio 1.65
INFI Yearly Current Assets VS Current LiabilitesINFI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M 80M 100M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. INFI Growth Analysis

3.1 Past

  • INFI shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 5.66%.
  • The Revenue has grown by 15.88% in the past year. This is quite good.
  • Measured over the past years, INFI shows a very negative growth in Revenue. The Revenue has been decreasing by -15.45% on average per year.
EPS 1Y (TTM)5.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%17.61%
Revenue 1Y (TTM)15.88%
Revenue growth 3Y-4.74%
Revenue growth 5Y-15.45%
Sales Q2Q%-15.01%

3.2 Future

  • Based on estimates for the next years, INFI will show a quite strong growth in Earnings Per Share. The EPS will grow by 12.63% on average per year.
  • Based on estimates for the next years, INFI will show a very strong growth in Revenue. The Revenue will grow by 83.41% on average per year.
EPS Next Y6.16%
EPS Next 2Y-5.92%
EPS Next 3Y12.63%
EPS Next 5YN/A
Revenue Next Year1.89%
Revenue Next 2Y14.92%
Revenue Next 3Y-25.99%
Revenue Next 5Y83.41%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
INFI Yearly Revenue VS EstimatesINFI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2026 2027 2028 2029 2030 50M 100M 150M
INFI Yearly EPS VS EstimatesINFI Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -0.5 -1 -1.5 -2 -2.5

More info and screens

Find the best growth stocksShow best growing peers

0

4. INFI Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for INFI. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for INFI. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
INFI Price Earnings VS Forward Price EarningsINFI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
INFI Per share dataINFI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.1 -0.2 -0.3 -0.4 -0.5

4.3 Compensation for Growth

  • A more expensive valuation may be justified as INFI's earnings are expected to grow with 12.63% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-5.92%
EPS Next 3Y12.63%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. INFI Dividend Analysis

5.1 Amount

  • INFI does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

INFI Fundamentals: All Metrics, Ratios and Statistics

INFINITY PHARMACEUTICALS INC

NASDAQ:INFI (9/13/2023, 8:17:37 PM)

After market: 0.04 0 (-10.51%)

0.0447

-0.04 (-46.98%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-08
Earnings (Next)11-13
Inst Owners0%
Inst Owner Change0%
Ins Owners3.33%
Ins Owner Change0%
Market Cap4.06M
Revenue(TTM)2.57M
Net Income(TTM)-40.95M
Analysts43.33
Price Target0.31 (593.51%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-12.04%
Min EPS beat(2)-12.04%
Max EPS beat(2)-12.04%
EPS beat(4)0
Avg EPS beat(4)-110.56%
Min EPS beat(4)-223.56%
Max EPS beat(4)-12.04%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)60.27%
Min Revenue beat(2)-18.35%
Max Revenue beat(2)138.89%
Revenue beat(4)1
Avg Revenue beat(4)5.14%
Min Revenue beat(4)-88.72%
Max Revenue beat(4)138.89%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)4%
EPS NY rev (1m)0%
EPS NY rev (3m)5.15%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)100%
Revenue NY rev (1m)0%
Revenue NY rev (3m)100%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.58
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.5
EYN/A
EPS(NY)-0.56
Fwd EYN/A
FCF(TTM)-0.43
FCFYN/A
OCF(TTM)-0.43
OCFYN/A
SpS0.03
BVpS-0.41
TBVpS-0.41
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 39.7%
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.12
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0%
Cap/Sales 0%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.65
Quick Ratio 1.65
Altman-Z -63.75
F-Score4
WACC9.35%
ROIC/WACCN/A
Cap/Depr(3y)2%
Cap/Depr(5y)231.2%
Cap/Sales(3y)0.42%
Cap/Sales(5y)15.58%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)5.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%17.61%
EPS Next Y6.16%
EPS Next 2Y-5.92%
EPS Next 3Y12.63%
EPS Next 5YN/A
Revenue 1Y (TTM)15.88%
Revenue growth 3Y-4.74%
Revenue growth 5Y-15.45%
Sales Q2Q%-15.01%
Revenue Next Year1.89%
Revenue Next 2Y14.92%
Revenue Next 3Y-25.99%
Revenue Next 5Y83.41%
EBIT growth 1Y9.92%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y1.4%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y1.4%
OCF growth 3YN/A
OCF growth 5YN/A

INFINITY PHARMACEUTICALS INC / INFI Fundamental Analysis FAQ

What is the fundamental rating for INFI stock?

ChartMill assigns a fundamental rating of 1 / 10 to INFI.


Can you provide the valuation status for INFINITY PHARMACEUTICALS INC?

ChartMill assigns a valuation rating of 0 / 10 to INFINITY PHARMACEUTICALS INC (INFI). This can be considered as Overvalued.


What is the profitability of INFI stock?

INFINITY PHARMACEUTICALS INC (INFI) has a profitability rating of 1 / 10.


What is the expected EPS growth for INFINITY PHARMACEUTICALS INC (INFI) stock?

The Earnings per Share (EPS) of INFINITY PHARMACEUTICALS INC (INFI) is expected to grow by 6.16% in the next year.